1
|
Offer KS, Dixon CE, Sutton DGM. Treatment of equine sarcoids: A systematic review. Equine Vet J 2024; 56:12-25. [PMID: 36917551 DOI: 10.1111/evj.13935] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2022] [Accepted: 03/09/2023] [Indexed: 03/15/2023]
Abstract
BACKGROUND The sarcoid is the most common equine cutaneous neoplasm. Evidence-based treatment of this condition is often lacking, and selection of treatment modality based on clinical experience or anecdotal evidence. OBJECTIVES To assess the quality of the currently available best evidence regarding the treatment of the equine sarcoid. STUDY DESIGN Systematic review. METHODS In compliance with PRISMA guidelines, literature searches were performed in PUBMED, Web of Science, CAB Abstracts, EMBASE (Ovid) and Scopus in April 2021. Included papers were required to describe an interventional study examining sarcoid treatment strategy, of level 4 evidence or greater. The case definition required confirmation of at least some included lesions on histopathology, and a minimum of 6 months of follow-up was required on treated cases. Studies were assessed by two independent reviewers (KO, CD). Data extraction was performed manually, followed by risk of bias assessment. Methodological quality was assessed using the GRADE system. RESULTS In total, 10 studies were included in the review. Case definition was confirmed via histopathology in all included lesions in 60% of papers. Time to follow-up was variably reported. Overall risk of bias ranged from 'some concerns' to 'critical'. Reported sarcoid regression rate ranged from 28% to 100% on an individual sarcoid level, and 9%-100% on a whole horse level. Transient local inflammation was reported following most treatment strategies, with further adverse events reported infrequently. MAIN LIMITATIONS Review methodology excluded a large proportion of available literature regarding the equine sarcoid. Significant heterogeneity between included studies prevented quantitative synthesis and most included papers were at significant risk of bias, indirectness, and imprecision. CONCLUSIONS There is insufficient evidence currently available to recommend one sarcoid treatment over another. There is an urgent need for sufficiently powered, randomised, placebo-controlled trials in order to allow more definitive comparison of the efficacy of different treatment strategies.
Collapse
Affiliation(s)
- Katie S Offer
- School of Biodiversity, One Health and Veterinary Medicine, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, UK
| | - Claire E Dixon
- Tufts Equine Center at the Hospital for Large Animals, Cummings School of Veterinary Medicine at Tufts University, North Grafton, Massachusetts, USA
| | - David G M Sutton
- School of Biodiversity, One Health and Veterinary Medicine, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, UK
| |
Collapse
|
2
|
Jindra C, Hainisch EK, Brandt S. Immunotherapy of Equine Sarcoids—From Early Approaches to Innovative Vaccines. Vaccines (Basel) 2023; 11:vaccines11040769. [PMID: 37112681 PMCID: PMC10145708 DOI: 10.3390/vaccines11040769] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2023] [Revised: 03/23/2023] [Accepted: 03/27/2023] [Indexed: 04/03/2023] Open
Abstract
Horses and other equid species are frequently affected by bovine papillomavirus type 1 and/or 2 (BPV1, BPV2)-induced skin tumors termed sarcoids. Although sarcoids do not metastasize, they constitute a serious health problem due to their BPV1/2-mediated resistance to treatment and propensity to recrudesce in a more severe, multiple form following accidental or iatrogenic trauma. This review provides an overview on BPV1/2 infection and associated immune escape in the equid host and presents early and recent immunotherapeutic approaches in sarcoid management.
Collapse
|
3
|
Saba C, Eggleston R, Parks A, Peroni J, Sjoberg E, Rice S, Tyma J, Williams J, Grosenbaugh D, Leard AT. ALVAC-fIL2, a feline interleukin-2 immunomodulator, as a treatment for sarcoids in horses: A pilot study. J Vet Intern Med 2022; 36:1179-1184. [PMID: 35416353 PMCID: PMC9151478 DOI: 10.1111/jvim.16425] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2021] [Revised: 03/16/2022] [Accepted: 03/25/2022] [Indexed: 12/19/2022] Open
Abstract
Background Sarcoid tumors are common in horses and may negatively impact the performance and value of the horse. No known treatment is reliably successful. Hypotheses/Objectives To determine tolerability, overall response rate, time to response, and progression‐free survival of horses with biopsy‐confirmed or suspected sarcoids treated with ALVAC‐fIL2. Animals Client‐owned horses with measurable, presumed‐ or biopsy‐confirmed sarcoid tumors. Methods Prospective pilot study. One milliliter of ALVAC‐fIL2 was injected into 4 to 5 areas of the sarcoid(s) in each horse (week 0); this treatment was repeated in weeks 1, 3, and 7. Sarcoids were measured at each visit, and response to treatment was determined according to the Response Evaluation Criteria in Solid Tumors for dogs (v1.0). After the final treatment, horses were reassessed and sarcoids remeasured every 3 months until tumor progression or for a minimum of 1 year if progression was not documented. Results Fourteen horses were included. Tumor size decreased in 86% of the horses, and the median time to first response was 89 days (range, 34‐406 days). Median time to best response was 211 days (range, 56‐406 days), but 3 of the sarcoids still were decreasing in size at the time of final evaluation. The median progression‐free interval was not reached. Adverse events were minimal and included transient focal inflammation in 2 horses. Conclusions and Clinical Importance Intratumoral injection of ALVAC‐fIL2 has promise as a well‐tolerated and effective, tissue‐sparing treatment for horses with sarcoid tumors.
Collapse
Affiliation(s)
- Corey Saba
- Department of Large Animal Medicine and Surgery, University of Georgia College of Veterinary Medicine, Athens, Georgia, USA
| | - Randall Eggleston
- Department of Large Animal Medicine and Surgery, University of Georgia College of Veterinary Medicine, Athens, Georgia, USA
| | - Andrew Parks
- Department of Large Animal Medicine and Surgery, University of Georgia College of Veterinary Medicine, Athens, Georgia, USA
| | - John Peroni
- Department of Large Animal Medicine and Surgery, University of Georgia College of Veterinary Medicine, Athens, Georgia, USA
| | - Eric Sjoberg
- Maggie's Menagerie Veterinary Services, Ila, Georgia, USA
| | - Shelbe Rice
- Maggie's Menagerie Veterinary Services, Ila, Georgia, USA
| | - Jesse Tyma
- Department of Large Animal Medicine and Surgery, University of Georgia College of Veterinary Medicine, Athens, Georgia, USA
| | - Jarred Williams
- Department of Large Animal Medicine and Surgery, University of Georgia College of Veterinary Medicine, Athens, Georgia, USA
| | | | | |
Collapse
|
4
|
Loschelder-Ostrowski J, Winter JC, Merle R, Klopfleisch R, Gehlen H. Treatment of equine sarcoids using recombinant poxviruses expressing feline interleukin-2. Vet Dermatol 2021; 32:283-e77. [PMID: 33728715 DOI: 10.1111/vde.12941] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2019] [Revised: 10/14/2020] [Accepted: 11/22/2020] [Indexed: 11/29/2022]
Abstract
BACKGROUND Interleukin (IL)-2 stimulates antitumour immunity and is successfully used for the treatment of different neoplasias. HYPOTHESIS/OBJECTIVES Canarypox virus locally expressing feline IL-2 is safe and can be used to treat equine sarcoids. ANIMALS Twenty horses of different breeds with a median age of eight years (interquartile range 6.0-13.3 years) and a total number of 59 sarcoids were included in the study. METHODS In this prospective clinical trial, sarcoids were injected twice seven days apart, with a recombinant canarypox virus expressing feline IL-2. Complete blood counts (CBC) and fibrinogen levels were measured before treatment and on days 1, 2, 7 and 8. RESULTS Complete regression was achieved in eight horses (40%) and partial regression in two horses (10%). No change in sarcoid size was observed in two horses (10%) and the disease progressed in five horses (25%). Sarcoids of three horses (15%) showed initial response followed by tumour growth. There were no significant changes in CBC and fibrinogen levels after either injection. One horse developed a mild fever the day after each injection, which subsided without treatment the following day. CONCLUSIONS Treatment of equine sarcoids with recombinant canarypox virus expressing feline IL-2 seems to be a safe therapy option. Although the expression of IL-2 after vector injection and its biological activity in horses were not proven in this study, the treatment resulted in regression and partial regression in 50% of the cases. Further studies are necessary to verify these findings and to establish a treatment protocol.
Collapse
Affiliation(s)
| | | | - Roswitha Merle
- Department of Epidemiology, Free University of Berlin, Königsweg 67, Berlin, 14163, Germany
| | - Robert Klopfleisch
- Department of Veterinary Pathology, Free University of Berlin, Robert-von-Ostertag-Str. 15, Berlin, 14163, Germany
| | - Heidrun Gehlen
- Clinic for Horses, Free University of Berlin, Oertzenweg 19b, Berlin, 14163, Germany
| |
Collapse
|
5
|
Merlano MC, Abbona A, Paccagnella M, Falletta A, Granetto C, Ricci V, Fea E, Denaro N, Ruatta F, Merlotti A, Bertetto O, Crosetto N, Galizia D, Basiricò M, Gammaitoni L, Sangiolo D, Aglietta M, Garrone O. Cytokine Profiling of End Stage Cancer Patients Treated with Immunotherapy. Vaccines (Basel) 2021; 9:vaccines9030235. [PMID: 33800511 PMCID: PMC7999072 DOI: 10.3390/vaccines9030235] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2021] [Revised: 03/04/2021] [Accepted: 03/06/2021] [Indexed: 01/22/2023] Open
Abstract
Published data suggest that immunotherapy plays a role even in patients with very advanced tumours. We investigated the immune profile of end-stage cancer patients treated with immunotherapy to identify changes induced by treatment. Breast, colon, renal and prostate cancer patients were eligible. Treatment consisted of metronomic cyclophosphamide, low-dose interleukin-2 (IL-2) and a single radiation shot. A panel of 16 cytokines was assessed using automated ELISA before treatment (T0), after radiation (RT; T1), at cycle 2 (T2) and at disease progression (TPD). Receiving operating characteristic (ROC) analysis was used to identify cytokine cut-off related to overall survival (OS). Principal component analysis (PCA) was used to identify the immune profile correlating better with OS and progression-free survival. Twenty-three patients were enrolled. High IL-2, low IL-8 and CCL-2 correlated with OS. The PCA identified a cluster of patients, with high IL-2, IL-12 and IFN-γ levels at T0 having longer PFS and OS. In all cohorts, IL-2 and IL-5 increased from T0 to T2; a higher CCL-4 level compared to T2 and a higher IL-8 level compared to T0 were found at TPD. The progressive increase of the IL-10 level during treatment negatively correlated with OS. Our data suggested that baseline cytokine levels may predict patients’ outcome and that the treatment may affect their kinetic even in end-stage patients. Cytokine profiling of end-stage patients might offer a tool for medical decisions (EUDRACT: 2016-000578-39).
Collapse
Affiliation(s)
- Marco Carlo Merlano
- Experimental Cell Therapy Lab, Department of Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, 10060 Turin, Italy; (L.G.); (D.S.); (M.A.)
- Correspondence: or ; Tel.: +39-0171-616342
| | - Andrea Abbona
- Translational Oncology, ARCO Foundation, 12100 Cuneo, Italy; (A.A.); (M.P.); (A.F.); (O.G.)
| | - Matteo Paccagnella
- Translational Oncology, ARCO Foundation, 12100 Cuneo, Italy; (A.A.); (M.P.); (A.F.); (O.G.)
| | - Antonella Falletta
- Translational Oncology, ARCO Foundation, 12100 Cuneo, Italy; (A.A.); (M.P.); (A.F.); (O.G.)
| | - Cristina Granetto
- Department of Medical Oncology, S. Croce e Carle Teaching Hospital, 12100 Cuneo, Italy; (C.G.); (V.R.); (E.F.); (N.D.); (F.R.)
| | - Vincenzo Ricci
- Department of Medical Oncology, S. Croce e Carle Teaching Hospital, 12100 Cuneo, Italy; (C.G.); (V.R.); (E.F.); (N.D.); (F.R.)
| | - Elena Fea
- Department of Medical Oncology, S. Croce e Carle Teaching Hospital, 12100 Cuneo, Italy; (C.G.); (V.R.); (E.F.); (N.D.); (F.R.)
| | - Nerina Denaro
- Department of Medical Oncology, S. Croce e Carle Teaching Hospital, 12100 Cuneo, Italy; (C.G.); (V.R.); (E.F.); (N.D.); (F.R.)
| | - Fiorella Ruatta
- Department of Medical Oncology, S. Croce e Carle Teaching Hospital, 12100 Cuneo, Italy; (C.G.); (V.R.); (E.F.); (N.D.); (F.R.)
| | - Anna Merlotti
- Department of Radiotherapy, S. Croce e Carle Teaching Hospital, 12100 Cuneo, Italy;
| | - Oscar Bertetto
- Rete Oncologica del Piemonte e Della Valle d’Aosta, 10125 Turin, Italy;
| | - Nicola Crosetto
- Department of Medical Biochemistry and Biophysiscs, Karolinska Institute, 17177 Stockholm, Sweden;
| | - Danilo Galizia
- Multidisciplinary Oncology Outpatient Clinic, Candiolo Cancer Institute, FPO-IRCCS, 10060 Turin, Italy;
| | - Marco Basiricò
- Department of Oncology, University of Turin, 10043 Turin, Italy;
| | - Loretta Gammaitoni
- Experimental Cell Therapy Lab, Department of Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, 10060 Turin, Italy; (L.G.); (D.S.); (M.A.)
| | - Dario Sangiolo
- Experimental Cell Therapy Lab, Department of Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, 10060 Turin, Italy; (L.G.); (D.S.); (M.A.)
- Department of Oncology, University of Turin, 10043 Turin, Italy;
| | - Massimo Aglietta
- Experimental Cell Therapy Lab, Department of Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, 10060 Turin, Italy; (L.G.); (D.S.); (M.A.)
- Department of Oncology, University of Turin, 10043 Turin, Italy;
| | - Ornella Garrone
- Translational Oncology, ARCO Foundation, 12100 Cuneo, Italy; (A.A.); (M.P.); (A.F.); (O.G.)
- Breast Unit, S. Croce e Carle Teaching Hospital, 12100 Cuneo, Italy
| |
Collapse
|
6
|
Brosnahan MM. Eosinophils of the horse: Part II: Eosinophils in clinical diseases. EQUINE VET EDUC 2020. [DOI: 10.1111/eve.13262] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Affiliation(s)
- M. M. Brosnahan
- College of Veterinary Medicine Midwestern University Glendale Arizona USA
| |
Collapse
|
7
|
Freer H, Hillegas JM, Wimer C, Baldwin C, LaBresh J, Wagner B. A monoclonal antibody for detection of intracellular and secreted interleukin-2 in horses. Vet Immunol Immunopathol 2017; 191:30-35. [PMID: 28895863 DOI: 10.1016/j.vetimm.2017.07.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2017] [Revised: 07/26/2017] [Accepted: 07/30/2017] [Indexed: 01/03/2023]
Abstract
Interleukin-2 (IL-2) is a T cell growth factor and major modulator of T helper (Th) cell differentiation. Here, we have developed and characterized a monoclonal antibody to equine IL-2 (anti-IL-2 mAb, clone 158-1). The IL-2 mAb detected rIL-2 by ELISA, intracellular staining and flow cytometry analysis and Western blotting. The IL-2 mAb was also paired with a polyclonal IL-2 detection antibody in both ELISA and a fluorescent bead-based assay. When these two assays were compared using identical reagents there was an improved analytical sensitivity (46pg/ml) and wider linear quantification range (46-100,000pg/ml) of IL-2 quantification using the fluorescent bead assay. Equine rIL-2 standards were expressed in both yeast and mammalian cells but the mammalian cell-expressed rIL-2 standard was found to be most accurate for native IL-2 quantification. Using this system we found that stimulation of equine peripheral blood mononuclear cells (PBMC) with phorbol 12-myristate 13-acetate (PMA) and ionomycin induced IL-2 secretion most potently. Pokeweed mitogen (PWM) consistently resulted in low amounts of IL-2 from PBMC, while concanavalin A (ConA), phytohemagglutinin-L (PHA-L) and lipopolysaccharide (LPS) either marginally stimulated or failed to stimulate IL-2 secretion from equine PBMC. After stimulation of equine PBMC with PMA and ionomycin, IL-2 production was detected in 13.0% (range 7.5-16.8%) of the lymphocytes by flow cytometric analysis. IL-2 expression was mainly stimulated in CD4+ cells, in a sub-population of CD8+ cells, and also in CD4-/CD8- cell population. In addition, both IFN-γ+/IL-2+ and IL-4+/IL-2+ producing cells were observed. Testing of serum and colostrum samples from 15 healthy horses showed that IL-2 was not detectable in these samples (<46pg/ml). In summary, the equine IL-2 mAb provides a new tool for the characterization of IL-2 producing equine cells and the quantification of secreted equine IL-2 in sensitive assays.
Collapse
Affiliation(s)
- Heather Freer
- Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA
| | - Julia M Hillegas
- Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA
| | - Christine Wimer
- Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA
| | - Cynthia Baldwin
- Paige Laboratory, Department of Veterinary and Animal Sciences, University of Massachusetts, Amherst, MA, USA
| | | | - Bettina Wagner
- Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA.
| |
Collapse
|
8
|
|
9
|
Haagsman AN, Witkamp ACS, Sjollema BE, Kik MJL, Kirpensteijn J. The effect of interleukin-2 on canine peripheral nerve sheath tumours after marginal surgical excision: a double-blind randomized study. BMC Vet Res 2013; 9:155. [PMID: 23927575 PMCID: PMC3751239 DOI: 10.1186/1746-6148-9-155] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2013] [Accepted: 07/31/2013] [Indexed: 11/10/2022] Open
Abstract
Background The objective of this study was to evaluate the effect on outcomes of intraoperative recombinant human interleukin-2 injection after surgical resection of peripheral nerve sheath tumours. In this double-blind trial, 40 patients due to undergo surgical excision (<5 mm margins) of presumed peripheral nerve sheath tumours were randomized to receive intraoperative injection of interleukin-2 or placebo into the wound bed. Results There were no significant differences in any variable investigated or in median survival between the two groups. The median recurrence free interval was 874 days (range 48–2141 days), The recurrence-free interval and overall survival time were significantly longer in dogs that undergone the primary surgery by a specialist-certified surgeon compared to a referring veterinarian regardless of whether additional adjunct therapy was given. Conclusion Overall, marginal excision of peripheral nerve sheath tumours in dogs resulted in a long survival time, but adjuvant treatment with recombinant human interleukin-2 (rhIL-2) did not provide a survival advantage.
Collapse
|
10
|
Abstract
Ocular squamous cell carcinoma (OSCC) in animals is a primary neoplasm of epithelial origin. OSCC or "cancer eye" is the most common malignant tumor affecting cattle in North America and is responsible for significant economic losses. In the United States, the prevalence of OSCC varies geographically and is higher in the southwestern region and in lower latitudes with higher levels of sunlight. Control of this disease would be of considerable significance to the economics and profitability of the beef and dairy cattle industries. This article reviews the characteristics of the most commonly affected animals, the factors that are believed to contribute to the development of OSCC, and the treatment options that have been proposed.
Collapse
Affiliation(s)
- Hiroki Tsujita
- Department of Small and Large Animal Sciences, Comparative Ophthalmology Service, University of Florida, College of Veterinary Medicine, PO Box 100126 Gainesville, FL 32610-0126, USA
| | | |
Collapse
|
11
|
Steinbach F, Bischoff S, Freund H, Metzner-Flemisch S, Ibrahim S, Walter J, Wilke I, Mauel S. Clinical application of dendritic cells and interleukin-2 and tools to study activated T cells in horses--first results and implications for quality control. Vet Immunol Immunopathol 2008; 128:16-23. [PMID: 19056130 DOI: 10.1016/j.vetimm.2008.10.317] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Dendritic cells (DCs) are antigen-presenting cells, which are well known for their capacity to stimulate immunity. The ex vivo generation of myeloid DC from monocytes has facilitated the development of DC-vaccination protocols which have been extensively evaluated in tumour immunology and are regarded by some as a gold mine for clinical research. However, there is a considerable amount of work required to overcome the potential risks associated with such therapy. It is therefore mandatory to characterize the system to be applied and to study the reactions, particularly at the level of T cell responses. The first objective of the current study was to test if tumour lysates loaded autologous DC or recombinant human IL-2 are well tolerated in horses and performed an exploratory phase I study on equine sarcoids and squamous cell carcinomas. We consequently intended to establish a robust protocol for the magnetic separation of monocytes such as in use in human clinical studies. Finally we intended to address the limits in the reagents to study equine T cell based immune reactions, and analysed markers for CD25 and FoxP3. The data showed that local application of DC or IL-2 did not cause side effects. Additionally our data show that a polyclonal approach to detect antigens such as CD25 might be successful, where mAbs are not available. Our data also demonstrate that the mAb FJK16s, which has been used successfully in rodents, humans, and dogs, can also be applied in horses. We finally wish to share our concerns regarding quality control for clinical studies and encourage multi-central studies such as in human medicine to ensure that progress along established standards is made for the benefit of veterinary medicine.
Collapse
Affiliation(s)
- Falko Steinbach
- Virology Department, Veterinary Laboratories Agency (VLA), Woodham Lane, New Haw, Addlestone, Surrey KT15 3NB, UK.
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Den Otter W, Jacobs JJL, Battermann JJ, Hordijk GJ, Krastev Z, Moiseeva EV, Stewart RJE, Ziekman PGPM, Koten JW. Local therapy of cancer with free IL-2. Cancer Immunol Immunother 2008; 57:931-50. [PMID: 18256831 PMCID: PMC2335290 DOI: 10.1007/s00262-008-0455-z] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2007] [Accepted: 01/14/2008] [Indexed: 12/30/2022]
Abstract
This is a position paper about the therapeutic effects of locally applied free IL-2 in the treatment of cancer. Local therapy: IL-2 therapy of cancer was originally introduced as a systemic therapy. This therapy led to about 20% objective responses. Systemic therapy however was very toxic due to the vascular leakage syndrome. Nevertheless, this treatment was a break-through in cancer immunotherapy and stimulated some interesting questions: Supposing that the mechanism of IL-2 treatment is both proliferation and tumoricidal activity of the tumor infiltrating cells, then locally applied IL-2 should result in a much higher local IL-2 concentration than systemic IL-2 application. Consequently a greater beneficial effect could be expected after local IL-2 application (peritumoral = juxtatumoral, intratumoral, intra-arterial, intracavitary, or intratracheal = inhalation). Free IL-2: Many groups have tried to prepare a more effective IL-2 formulation than free IL-2. Examples are slow release systems, insertion of the IL-2 gene into a tumor cell causing prolonged IL-2 release. However, logistically free IL-2 is much easier to apply; hence we concentrated in this review and in most of our experiments on the use of free IL-2. Local therapy with free IL-2 may be effective against transplanted tumors in experimental animals, and against various spontaneous carcinomas, sarcomas, and melanoma in veterinary and human cancer patients. It may induce rejection of very large, metastasized tumor loads, for instance advanced clinical tumors. The effects of even a single IL-2 application may be impressive. Not each tumor or tumor type is sensitive to local IL-2 application. For instance transplanted EL4 lymphoma or TLX9 lymphoma were not sensitive in our hands. Also the extent of sensitivity differs: In Bovine Ocular Squamous Cell Carcinoma (BOSCC) often a complete regression is obtained, whereas with the Bovine Vulval Papilloma and Carcinoma Complex (BVPCC) mainly stable disease is attained. Analysis of the results of local IL-2 therapy in 288 cases of cancer in human patients shows that there were 27% Complete Regressions (CR), 23% Partial Regressions (PR), 18% Stable Disease (SD), and 32% Progressive Disease (PD). In all tumors analyzed, local IL-2 therapy was more effective than systemic IL-2 treatment. Intratumoral IL-2 applications are more effective than peritumoral application or application at a distant site. Tumor regression induced by intratumoral IL-2 application may be a fast process (requiring about a week) in the case of a highly vascular tumor since IL-2 induces vascular leakage/edema and consequently massive tumor necrosis. The latter then stimulates an immune response. In less vascular tumors or less vascular tumor sites, regression may require 9-20 months; this regression is mainly caused by a cytotoxic leukocyte reaction. Hence the disadvantageous vascular leakage syndrome complicating systemic treatment is however advantageous in local treatment, since local edema may initiate tumor necrosis. Thus the therapeutic effect of local IL-2 treatment is not primarily based on tumor immunity, but tumor immunity seems to be useful as a secondary component of the IL-2 induced local processes. If local IL-2 is combined with surgery, radiotherapy or local chemotherapy the therapeutic effect is usually greater than with either therapy alone. Hence local free IL-2 application can be recommended as an addition to standard treatment protocols. Local treatment with free IL-2 is straightforward and can readily be applied even during surgical interventions. Local IL-2 treatment is usually without serious side effects and besides minor complaints it is generally well supported. Only small quantities of IL-2 are required. Hence the therapy is relatively cheap. A single IL-2 application of 4.5 million U IL-2 costs about 70 Euros. Thus combined local treatment may offer an alternative in those circumstances when more expensive forms of treatment are not available, for instance in resource poor countries.
Collapse
Affiliation(s)
- Willem Den Otter
- Department of Pathobiology, Faculty of Veterinary Medicine, Utrecht University, Yalelaan 1, 3584 CL Utrecht, The Netherlands.
| | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Théon AP, Wilson WD, Magdesian KG, Pusterla N, Snyder JR, Galuppo LD. Long-term outcome associated with intratumoral chemotherapy with cisplatin for cutaneous tumors in equidae: 573 cases (1995–2004). J Am Vet Med Assoc 2007; 230:1506-13. [PMID: 17504043 DOI: 10.2460/javma.230.10.1506] [Citation(s) in RCA: 63] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVE To determine outcome associated with cutaneous tumors treated via intratumoral chemotherapy with cisplatin and identify risk factors affecting local tumor control and complications in equidae. DESIGN Retrospective case series. ANIMALS 573 equidae with 630 cutaneous tumors. PROCEDURES Medical records of horses, mules, donkeys, and ponies with cutaneous tumors treated via intratumoral chemotherapy with cisplatin were analyzed. RESULTS 549 horses, 13 mules, 8 donkeys, and 3 ponies with 630 histologically confirmed cutaneous tumors were included. Tumors included sarcoids (n = 409), squamous cell carcinomas (151), soft tissue sarcomas (28), cutaneous lymphomas (26), and melanomas (16). Overall cure rate, defined as local control at 4 years, was 93.3%. For all tumor stages combined, cure rates after 1 course of treatment were 96.3% for sarcoids, 96% for lymphomas, 88% for squamous cell carcinomas, 85% for soft tissue sarcomas, and 81% for melanomas. Treatment protocol, tumor stage, and prior treatment were significant prognostic factors for tumor control. Treatment efficacy was lower for large tumors, those with gross postoperative residual disease, and those that had been treated previously with other modalities. Treatment was well tolerated. Local reactions were more likely to occur and to be more severe after the third and fourth treatment sessions. CONCLUSIONS AND CLINICAL RELEVANCE Results confirmed the value of intratumoral chemotherapy with cisplatin for treatment of cutaneous tumors in equidae. The results cannot be extrapolated to other formulations of cisplatin or other protocols that might be used.
Collapse
Affiliation(s)
- Alain P Théon
- Department of Surgery, School of Veterinary Medicine, University of California, Davis, CA 95616, USA
| | | | | | | | | | | |
Collapse
|
14
|
Nogueira SAF, Torres SMF, Malone ED, Diaz SF, Jessen C, Gilbert S. Efficacy of imiquimod 5% cream in the treatment of equine sarcoids: a pilot study. Vet Dermatol 2006; 17:259-65. [PMID: 16827669 DOI: 10.1111/j.1365-3164.2006.00526.x] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Imiquimod is an immune response modifier with potent antiviral and antitumour activity. The objective of this pilot study was to evaluate the efficacy of an imiquimod 5% cream (Aldaratrade mark: 3M, Saint Paul, MN, USA) as a topical treatment for equine sarcoids. Fifteen horses with a total of 19 tumours were enrolled, including mixed (7), fibroblastic (5), flat (3), verrucous (2), and nodular (2) types. Baseline data included history, physical examination, tumour location, measurement and digital photography. Imiquimod was applied by the owners three times a week until complete resolution of the tumour or 32 weeks, whichever occurred first. Tumours were measured and photographed every 4 weeks. Treatment efficacy was defined as 75% or greater reduction of tumour size by the end of the trial. Four sarcoids were withdrawn from the study. Twelve of the remaining 15 tumours (80%) showed more than 75% reduction in size and nine (60%) totally resolved between 8 and 32 weeks. The most common adverse effects of exudation, erythema, erosions, depigmentation and alopecia were limited to the tumour and adjacent areas. The results suggest that topical imiquimod is a therapeutic option for the treatment of equine sarcoids, although more detailed studies are required to corroborate these initial findings.
Collapse
Affiliation(s)
- Sandra A F Nogueira
- Veterinary Clinical Sciences Department, University of Minnesota, Saint Paul, Minnesota 55108, USA.
| | | | | | | | | | | |
Collapse
|
15
|
Krastev Z, Koltchakov V, Tomova R, Deredjian S, Alexiev A, Popov D, Tomov B, Koten JW, Jacobs J, Den Otter W. Locoregional IL-2 low dose applications for gastrointestinal tumors. World J Gastroenterol 2005; 11:5525-9. [PMID: 16222748 PMCID: PMC4320365 DOI: 10.3748/wjg.v11.i35.5525] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To explore the feasibility of local interleukin 2 (IL-2) in patients with different forms of abdominal cancer. This required experimentation with the time interval between IL-2 applications and the methods of application.
METHODS: Sixteen patients with stages III and IV of gastrointestinal malignancies (primary or metastatic) who were admitted to our Department of Gastroenterology were treated with locoregionally applied IL-2 in low doses.
RESULTS: No major problems applying locoregional IL-2 were encountered. In 6 out of 16 patients, a modest but clinically worthwhile improvement was obtained. Adverse effects were minimal. The therapeutic scheme was well tolerated, even in patients in a poor condition.
CONCLUSION: This study demonstrates the feasibility of low dose locoregional IL-2 application in advanced abdominal cancer. Local IL-2 therapy gives only negligible adverse effects. The results suggest that it is important to apply intratumorally. Local IL-2 may be given adjunct to standard therapeutic regimes and does not imply complex surgical interventions. These initial results are encouraging.
Collapse
|
16
|
Jacobs JJL, Sparendam D, Den Otter W. Local interleukin 2 therapy is most effective against cancer when injected intratumourally. Cancer Immunol Immunother 2005; 54:647-54. [PMID: 15685449 PMCID: PMC11033014 DOI: 10.1007/s00262-004-0627-4] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2004] [Accepted: 09/21/2004] [Indexed: 10/25/2022]
Abstract
Local interleukin 2 (IL-2) therapy is more effective against systemic tumours than systemic IL-2 therapy, but it remains unclear whether IL-2 should be injected intratumourally or peritumourally. To investigate this question, we treated DBA/2 mice bearing a large subcutaneous syngeneic SL2 lymphoma with either intra or peritumoural IL-2 therapy. Both applications enhanced survival, but intratumourally injected IL-2 was more effective than peritumourally injected IL-2. Tumours started to regress 4 days after IL-2 injection. Tumour cells died at the IL-2 injection site, although IL-2 is not directly cytotoxic for SL2 cells in vitro. Tumour cell death correlated well with oedema and extravascular erythrocytes, but less with leukocyte infiltrates. In mice bearing two s.c. tumours, intratumoural application therapy of IL-2 in one tumour caused decrease in size of both tumours in 4-9 days after therapy. However, the IL-2 treated tumours regressed more strongly than the untreated tumours. We conclude that vascular leakage and/or tissue destruction inside the tumour may contribute to the enhanced effect of intratumoural IL-2 therapy compared to peritumoural IL-2 therapy. Hence, we recommend applying of intratumoural rather than peritumoural IL-2 therapy.
Collapse
Affiliation(s)
- John J L Jacobs
- Department of Pathobiology, Faculty of Veterinary Medicine, P.O. Box 80.158, 3508 TD Utrecht, the Netherlands.
| | | | | |
Collapse
|
17
|
Stewart RJE, Masztalerz A, Jacobs JJL, Den Otter W. Local interleukin-2 and interleukin-12 therapy of bovine ocular squamous cell carcinomas. Vet Immunol Immunopathol 2005; 106:277-84. [PMID: 15963825 DOI: 10.1016/j.vetimm.2005.03.002] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2003] [Revised: 03/09/2005] [Accepted: 03/10/2005] [Indexed: 11/17/2022]
Abstract
Interleukin-2 and interleukin-12 have been used independently to successfully treat the induced and the spontaneous tumours in animals. This trial was done to determine if a combination of IL-2 and IL-12 in the treatment of spontaneous bovine ocular squamous cell carcinomas (BOSCC) would be more successful than IL-2 or IL-12 therapy by themselves. For this trial, we selected 25 BOSCC tumours seen on Holstein Fresian cows in Beatrice, Zimbabwe. The cows were randomly assigned to a treatment group of 5 days of IL-2 (200,000 U/day), 5 days of IL-12 (0.5 microg/day) or 5 days of IL-2 (200,000 U/day) and IL-12 (0.5 microg/day). At 20 months after treatment, the IL-2 therapy group had 63% complete regressions; the combination group had 38% complete regressions, which were significantly higher than the IL-12 group, which had 0% complete regressions at 20 months, despite having 29% complete regressions at 6 months. These results show that IL-2 therapy by itself and in combination with IL-12 is more successful than IL-12 by itself. However, combination therapy does not improve the outcome in comparison to IL-2 as a single therapy. It also proves that IL-2 is consistently successful in the therapy of BOSCC with over 60% complete regression, which corresponds to a number of other studies we have done on IL-2 therapy of BOSCC [Rutten, V.P.M.G., Klein, W.R., De Jong, W.A., Misdorp, W., Den Otter, W., Steerenberg, P.A., De Jong, W.H., Ruitenberg, E.J., 1989. Local interleukin-2 therapy in bovine ocular squamous cell carcinoma. A pilot study. Cancer Immunol. Immunother. 30, 165--169; Stewart, R.J.E., Hill, F.W.G., Masztalerz, A., Jacobs, J.J.L., Koten, J.W., Den Otter, W., 2003. Local low dose interleukin-2 therapy of bovine ocular squamous cell carcinomas in cattle in Zimbabwe, submitted for publication; Den Otter, W., Hill, F.W.G., Klein, W.R., Koten, J.W., Steerenberg, P.A., De Mulder, P.H.M., Rutten, V.P.M.G., Ruitenberg, E.J., 1993. Low doses of interleukin-2 can cure large bovine ocular squamous cell carcinoma. Anticancer Res. 13, 2453-2455; Den Otter, W., Hill, F.W.G., Klein, W.R., Koten, J.W., Steerenberg, P.A., De Mulder, P.H., Rhode, C., Stewart, R., Faber, J.A., Ruitenberg, E.J., 1995. Therapy of bovine ocular squamous cell carcinoma with local doses of interleukin-2: 67% complete regressions after 20 months of follow-up. Cancer Immunol. Immunother. 41, 10-14].
Collapse
Affiliation(s)
- Rachel J E Stewart
- Department of Clinical Veterinary Studies, University of Zimbabwe, Mount Pleasant, Harare, Zimbabwe.
| | | | | | | |
Collapse
|